What is Mineralys Therapeutics, Inc.'s cost not yet recognized?

Mineralys Therapeutics, Inc. (MLYS) reported cost not yet recognized of $48.7M in Q4 2025.

What is the long-term trend for Mineralys Therapeutics, Inc.'s cost not yet recognized?

Over 2 years (2023 to 2025), Mineralys Therapeutics, Inc.'s cost not yet recognized has grown at a 79.0% compound annual growth rate (CAGR), from $15.2M to $48.7M.

Mineralys Therapeutics, Inc. MLYS Cost not yet recognized

Cost not yet recognized at other companies

Aurinia PharmaceuticalsAUPH

——

Other financials

Income statement

See full

Operating income-$45.3M-2.0%

Net income-$39.3M+6.8%

EPS (diluted)-$0.47+40.5%

Balance sheet

See full

Cash & equivalents$1.2M-14.6%

Total equity$638.1M+86.8%

Total assets$652.9M+83.9%

Cash flow

See full

Operating cash flow-$39.5M+13.2%

CapEx$15.0K—

Free cash flow-$37.9M+43.3%

Valuation

See full

Market cap$2.27B+124%

Returns & leverage

See full

Return on equity-31%-9.6pp

Current ratio44.3×+17.8×

Where this comes from

Reported directly by Mineralys Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions.

The official record: Mineralys Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mineralys Therapeutics, Inc.'s cost not yet recognized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Mineralys Therapeutics, Inc.'s cost not yet recognized?: Mineralys Therapeutics, Inc. (MLYS) reported cost not yet recognized of $48.7M in Q4 2025.
What is the long-term trend for Mineralys Therapeutics, Inc.'s cost not yet recognized?: Over 2 years (2023 to 2025), Mineralys Therapeutics, Inc.'s cost not yet recognized has grown at a 79.0% compound annual growth rate (CAGR), from $15.2M to $48.7M.